Chari A, et al. - Among patients with relapsed or refractory multiple myeloma who have received 1-3 prior lines of therapy, including bortezomib and an immunomodulatory drug, researchers assessed daratumumab plus carfilzomib and dexamethasone (DKd). Lenalidomide-refractory patients were eligible for inclusion. Findings revealed good tolerability of D-Kd among patients. Low neutropenia rates were seen as well. An overall response rate of 84% and encouraging progression-free survival were achieved with D-Kd treatment, even in those refractory to lenalidomide. Thrombocytopenia (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%) were documented as the most commonly occurring grade 3/4 treatment-emergent adverse events.